🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Meet HiFiBiO Therapeutics at this year’s Pharma Partnering Summit on May 14th – 15th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!

May is #AAPIHeritageMonth! Join HiFiBiO to celebrate all the Asian Americans, Native Hawaiians, and Pacific Islanders that have contributed greatly to our shared history.

HiFiBiO Therapeutics will present Phase 1 clinical trial data for our first-in-class TNFR2 agonist (HFB200301) and next-generation OX40 agonist (HFB301001) for solid tumors at the upcoming #ASCO2024. Link to press release and abstract: hifibio.com/hifibio-therap…

Don't forget to stop by our two posters at #ASCO2024 as we release Phase 1 dose escalation data for our first-in-class TNFR2 agonist, HFB200301 and next-generation OX40 agonist HFB301001! Link to press release for details: lnkd.in/emRqZBs3

Meet HiFiBiO's Timothy Miller at the upcoming #BIO2024 International Convention on June 3rd to 6th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!

There was amazing buzz around our two posters at #ASCO2024! Our team enjoyed the exciting discussions around the results of our two Ph1 clinical trials for best-in-class TNFR2 agonist HFB200301 and next-generation OX40 agonist HFB301001. The e-posters are now up on our website

June is #NationalCancerSurvivorMonth. Join HiFiBiO Therapeutics in honoring the over 18 million individuals in the U.S. living with a history of cancer and the unique challenges they continue to face (AACR lnkd.in/g-p7KKU). Thanks to remarkable advances in cancer

Thrilled to have our CEO Liang Schweizer recognized among so many inspiring business leaders as a winner in the Entrepreneur Of The Year® New England program! hifibio.com/ey-announces-l… #EOYUS #EOYNE

Thrilled to have CEO Liang Schweizer selected as a Finalist for the Lifetime Achievement Award and HiFiBiO Therapeutics recognized as a Finalist for the Start-up of the Year Award at #BiotechWeekBoston!

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #ESMO2024 meeting, taking place Sep 13-17 in Barcelona, Spain. On Saturday, September 14, the company will present compelling Phase 1 trial data for two novel

HiFiBiO Therapeutics will present interim Phase 1 clinical trial data for our first-in-class TNFR2 agonist (HFB200301) and best-in-class BTLA antagonist for solid tumors at the upcoming #ESMO2024. Link to PR and abstract: hifibio.com/hifibio-therap…

Our team enjoyed the exciting conversations around our two posters at #ESMO2024! We are thrilled to share the amazing Ph1 clinical trial results for HFB200301, a first-in-class TNFR2 agonist and HFB200603, a best-in-class BTLA antagonist. The full posters are up on our website

Exciting news! Join us at the #BiotechWeekBoston (BWB) Awards next Monday, September 23, where we’re honored to be among the finalists for the Start-up of the Year Award! We’re also thrilled to announce that our CEO, Liang Schweizer, is named a Finalist for the prestigious

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #SITC2024 meeting, taking place Nov. 6-10 in Houston, Texas. The company will present Drug Intelligence Science (DIS®) enabled translational insights from ongoing

Come meet HiFiBiO's Timothy Miller at the upcoming #BIOEUROPE on November 4th to 6th in Stockholm, Sweden. Excited to connect and collaborate with fellow #biotech and #pharma leaders on partnership of our IO and I&I programs.

We are thrilled to share that the FDA has cleared our IND application for HFB200604, our first inflammation and immunology program! HFB200604 is a best-in-class BTLA agonist monoclonal antibody developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. It

We're so excited for #SITC2024! If you are also attending, don't forget to stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist

HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with NYSE 🏛 Floor Talks to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies through AI/ML to enhance the probability of success in patients suffering from cancer and